person · Reporting owner

Tipirneni Praveen P.

Disclosed activity across 4 companies

Tapewire entity: 36852
SEC CIK: 0001779978

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215	Director	June 16, 2026	June 18, 2026
Panacea Acquisition Corp. IIPANA · Entity 114006	Director	April 06, 2021	April 07, 2021
Tectonic Therapeutic, Inc.TECX · Entity 5328	Director	June 09, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BridgeBio Oncology Therapeutics, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.73 · Expires 2036-06-15	Direct	31,675	Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 31,675 · Balance 31,675 F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Panacea Acquisition Corp. II

Report date April 06, 2021 · Filed April 07, 2021

This filing explicitly reported no securities owned.

Tectonic Therapeutic, Inc.

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.56 · Expires 2036-06-08	Direct	10,200	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 10,200 · Balance 10,200 F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Morphic Holding, Inc.

Report date August 16, 2024 · Filed August 20, 2024

Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-08-16 transaction · row 1 1 source row Row 1 · 2024-08-16 · Other · Disposed 42,460 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
Common StockSEC Table I · non-derivative	IndirectBy The Praveen P. Tipirneni Irrevocable Trust of 2019	Reported balance After 2024-08-16 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-08-16 · Other · Disposed 614,474 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F3: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.32 · Expires 2028-12-14	Direct	Reported balance After 2024-08-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-16 · Disposition to issuer · Disposed 339,561 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.42 · Expires 2030-02-17	Direct	Reported balance After 2024-08-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-08-16 · Disposition to issuer · Disposed 273,350 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.19 · Expires 2031-01-14	Direct	Reported balance After 2024-08-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-08-16 · Disposition to issuer · Disposed 205,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Option vests as to 2.0833% of the total shares monthly, beginning February 15, 2021, with 100% of the total shares vested and exercisable on January 15, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.75 · Expires 2032-01-13	Direct	Reported balance After 2024-08-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-08-16 · Disposition to issuer · Disposed 224,016 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F7: The Option vests as to 2.0833% of the total shares monthly, beginning February 14, 2022, with 100% of the total shares vested and exercisable on January 14, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.72 · Expires 2033-01-12	Direct	Reported balance After 2024-08-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-08-16 · Disposition to issuer · Disposed 177,024 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F8: The Option vests as to 2.0833% of the total shares monthly, beginning February 13, 2023, with 100% of the total shares vested and exercisable on January 13, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.79 · Expires 2034-01-11	Direct	Reported balance After 2024-08-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-08-16 · Disposition to issuer · Disposed 206,400 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F9: The Option vests as to 2.0833% of the total shares monthly, beginning February 12, 2024, with 100% of the total shares vested and exercisable on January 12, 2028, subject to the reporting person's provision of service to the issuer on each vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-08-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-08-16 · Disposition to issuer · Disposed 88,500 · Balance 0 F10: Each Company Restricted Stock Unit ("RSUs") represents a contingent right to receive one (1) share of Common Stock upon settlement for no consideration. F12: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU. F11: The RSUs vest as to 25% of the total shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, subject to the reporting person's provision of service to the Issuer on each vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-08-16 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-08-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F10: Each Company Restricted Stock Unit ("RSUs") represents a contingent right to receive one (1) share of Common Stock upon settlement for no consideration. F12: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU. F13: The RSUs vest as to 25% of the total shares on each of January 14, 2023, January 14, 2024, January 14, 2025 and January 14, 2026, subject to the reporting person's provision of service to the Issuer on each vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-08-16 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-08-16 · Disposition to issuer · Disposed 136,800 · Balance 0 F10: Each Company Restricted Stock Unit ("RSUs") represents a contingent right to receive one (1) share of Common Stock upon settlement for no consideration. F12: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU. F14: The RSUs vest as to 25% of the total shares on each of January 12, 2025, January 12, 2026, January 12, 2027 and January 12, 2028, subject to the reporting person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F3: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

F4: The Company Stock Option ("Option") is fully vested.

F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F6: The Option vests as to 2.0833% of the total shares monthly, beginning February 15, 2021, with 100% of the total shares vested and exercisable on January 15, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.

F7: The Option vests as to 2.0833% of the total shares monthly, beginning February 14, 2022, with 100% of the total shares vested and exercisable on January 14, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.

F8: The Option vests as to 2.0833% of the total shares monthly, beginning February 13, 2023, with 100% of the total shares vested and exercisable on January 13, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.

F9: The Option vests as to 2.0833% of the total shares monthly, beginning February 12, 2024, with 100% of the total shares vested and exercisable on January 12, 2028, subject to the reporting person's provision of service to the issuer on each vesting date.

F10: Each Company Restricted Stock Unit ("RSUs") represents a contingent right to receive one (1) share of Common Stock upon settlement for no consideration.

F11: The RSUs vest as to 25% of the total shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, subject to the reporting person's provision of service to the Issuer on each vesting date.

F12: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU.

F13: The RSUs vest as to 25% of the total shares on each of January 14, 2023, January 14, 2024, January 14, 2025 and January 14, 2026, subject to the reporting person's provision of service to the Issuer on each vesting date.

F14: The RSUs vest as to 25% of the total shares on each of January 12, 2025, January 12, 2026, January 12, 2027 and January 12, 2028, subject to the reporting person's provision of service to the Issuer on each vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 14, 2023 Filed Jan 19, 2023 00:05 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	4,027	$30.63	$123,337.75	Disclosure SEC source: 0001209191-23-003856 · doc4.xml · nonDerivative · entry 2 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,679 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document
January 14, 2023 Filed Jan 19, 2023 00:05 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionCommon Stock	12,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-003856 · doc4.xml · nonDerivative · entry 1 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. Read SEC document
January 13, 2023 Filed Jan 19, 2023 00:05 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantRestricted Stock Unit · Derivative	118,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-003856 · doc4.xml · derivative · entry 4 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. F4 · derivative.expiration_date: The RSUs vest as to 25% of the total shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
January 13, 2023 Filed Jan 19, 2023 00:05 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantStock Option (right to buy Common Stock) · Derivative	177,024	$0.00 Strike: $31.72	$0.00	Disclosure SEC source: 0001209191-23-003856 · doc4.xml · derivative · entry 3 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,024 Underlying: Common Stock · 177,024 shares Expires 2033-01-12 F3 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 13, 2023, with 100% of the total shares vested and exercisable on January 13, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
January 14, 2022 Filed Jan 20, 2022 00:14 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantRestricted Stock Units (RSU) · Derivative	50,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-003853 · doc4.xml · derivative · entry 3 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-13 F3 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of January 14, 2023, January 14, 2024, January 14, 2025, and January 14, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
January 14, 2022 Filed Jan 20, 2022 00:14 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantStock Option (right to buy Common Stock) · Derivative	224,016	$0.00 Strike: $44.75	$0.00	Disclosure SEC source: 0001209191-22-003853 · doc4.xml · derivative · entry 2 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,016 Underlying: Common Stock · 224,016 shares Expires 2032-01-13 F2 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 14, 2022, with 100% of the total shares vested and exercisable on January 14, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
February 02, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionStock Option (right to buy Common Stock) · Derivative	11,932	$0.00 Strike: $4.32	$0.00	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · derivative · entry 13 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,785 Underlying: Common Stock · 11,932 shares Expires 2028-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning January 14, 2019, with 100% of the total shares vested and exercisable on December 14, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
February 02, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	100	$37.09	$3,709.00	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · nonDerivative · entry 11 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 614,474 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F5 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
February 02, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	2,772	$36.70	$101,735.17	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · nonDerivative · entry 10 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 614,574 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.09 to $37.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
February 02, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	5,128	$35.57	$182,419.37	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · nonDerivative · entry 9 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 617,346 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.05 to $36.04 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
February 02, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	4,203	$36.70	$154,261.87	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · nonDerivative · entry 8 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,286 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.16 to $37.09 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 02, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	7,729	$35.55	$274,769.81	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · nonDerivative · entry 7 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,489 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $36.095 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 02, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionCommon Stock	11,932	$4.32	$51,546.24	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · nonDerivative · entry 6 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 01, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionStock Option (right to buy Common Stock) · Derivative	4,000	$0.00 Strike: $4.32	$0.00	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · derivative · entry 12 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,717 Underlying: Common Stock · 4,000 shares Expires 2028-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning January 14, 2019, with 100% of the total shares vested and exercisable on December 14, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
February 01, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	1,900	$34.41	$65,383.56	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · nonDerivative · entry 5 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 622,474 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.06 to $34.82 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
February 01, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	2,100	$33.48	$70,318.29	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · nonDerivative · entry 4 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 624,374 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.03 to $33.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
February 01, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	1,799	$34.43	$61,934.35	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · nonDerivative · entry 3 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,286 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.06 to $34.91 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 01, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	2,201	$33.49	$73,707.75	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · nonDerivative · entry 2 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,085 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.02 to $33.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 01, 2021 Filed Feb 4, 2021 00:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionCommon Stock	4,000	$4.32	$17,280.00	Disclosure SEC source: 0001209191-21-007504 · doc4.xml · nonDerivative · entry 1 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 15, 2021 Filed Jan 20, 2021 00:06 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantStock Option (right to buy Common Stock) · Derivative	205,000	$0.00 Strike: $30.19	$0.00	Disclosure SEC source: 0001209191-21-004120 · doc4.xml · derivative · entry 1 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2031-01-14 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 15, 2021, with 100% of the total shares vested and exercisable on January 15, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
January 05, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionStock Option (right to buy Common Stock) · Derivative	1,653	$0.00 Strike: $4.32	$0.00	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · derivative · entry 12 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,717 Underlying: Common Stock · 1,653 shares Expires 2028-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning January 14, 2019, with 100% of the total shares vested and exercisable on December 14, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
January 05, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	300	$32.03	$9,607.53	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · nonDerivative · entry 10 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 626,474 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.29 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
January 05, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	1,304	$30.94	$40,343.93	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · nonDerivative · entry 9 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 626,774 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.67 to $31.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
January 05, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	300	$32.06	$9,618.03	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · nonDerivative · entry 8 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,813 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.80 to $32.29 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 05, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	1,353	$30.96	$41,894.97	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · nonDerivative · entry 7 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,113 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.61 to $31.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 05, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionCommon Stock	1,653	$4.32	$7,140.96	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · nonDerivative · entry 6 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionStock Option (right to buy Common Stock) · Derivative	2,347	$0.00 Strike: $4.32	$0.00	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · derivative · entry 11 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,370 Underlying: Common Stock · 2,347 shares Expires 2028-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning January 14, 2019, with 100% of the total shares vested and exercisable on December 14, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	600	$33.46	$20,075.16	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · nonDerivative · entry 5 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 628,078 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.11 to $33.94 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	1,796	$32.54	$58,439.15	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · nonDerivative · entry 4 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 628,678 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.10 to $33.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	400	$33.70	$13,479.00	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · nonDerivative · entry 3 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,813 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.96 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	1,947	$32.52	$63,323.06	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · nonDerivative · entry 2 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,213 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.09 to $33.02 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:56 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionCommon Stock	2,347	$4.32	$10,139.04	Disclosure SEC source: 0001209191-21-002354 · doc4.xml · nonDerivative · entry 1 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 22, 2020 Filed Dec 24, 2020 01:03 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionStock Option (right to buy Common Stock) · Derivative	2,268	$0.00 Strike: $4.32	$0.00	Disclosure SEC source: 0001209191-20-065121 · doc4.xml · derivative · entry 8 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,717 Underlying: Common Stock · 2,268 shares Expires 2028-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning January 14, 2019, with 100% of the total shares vested and exercisable on December 14, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
December 22, 2020 Filed Dec 24, 2020 01:03 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	2,268	$35.05	$79,490.22	Disclosure SEC source: 0001209191-20-065121 · doc4.xml · nonDerivative · entry 6 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,813 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.43 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 22, 2020 Filed Dec 24, 2020 01:03 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionCommon Stock	2,268	$4.32	$9,797.76	Disclosure SEC source: 0001209191-20-065121 · doc4.xml · nonDerivative · entry 5 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 22, 2020 Filed Dec 24, 2020 01:03 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	74	$35.00	$2,590.00	Disclosure SEC source: 0001209191-20-065121 · doc4.xml · nonDerivative · entry 4 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 630,474 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F3 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
December 21, 2020 Filed Dec 24, 2020 01:03 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionStock Option (right to buy Common Stock) · Derivative	200	$0.00 Strike: $4.32	$0.00	Disclosure SEC source: 0001209191-20-065121 · doc4.xml · derivative · entry 7 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,985 Underlying: Common Stock · 200 shares Expires 2028-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning January 14, 2019, with 100% of the total shares vested and exercisable on December 14, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
December 21, 2020 Filed Dec 24, 2020 01:03 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	240	$35.01	$8,401.99	Disclosure SEC source: 0001209191-20-065121 · doc4.xml · nonDerivative · entry 3 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 630,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.01 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
December 21, 2020 Filed Dec 24, 2020 01:03 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	200	$35.01	$7,002.00	Disclosure SEC source: 0001209191-20-065121 · doc4.xml · nonDerivative · entry 2 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,813 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. Read SEC document
December 21, 2020 Filed Dec 24, 2020 01:03 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionCommon Stock	200	$4.32	$864.00	Disclosure SEC source: 0001209191-20-065121 · doc4.xml · nonDerivative · entry 1 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 16, 2020 Filed Dec 19, 2020 01:27 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionStock Option (right to buy Common Stock) · Derivative	1,000	$0.00 Strike: $4.32	$0.00	Disclosure SEC source: 0001209191-20-064573 · doc4.xml · derivative · entry 4 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,185 Underlying: Common Stock · 1,000 shares Expires 2028-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning January 14, 2019, with 100% of the total shares vested and exercisable on December 14, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
December 16, 2020 Filed Dec 19, 2020 01:27 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	1,259	$35.13	$44,229.68	Disclosure SEC source: 0001209191-20-064573 · doc4.xml · nonDerivative · entry 3 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 630,788 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.06 to $35.57 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
December 16, 2020 Filed Dec 19, 2020 01:27 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	1,000	$35.20	$35,203.80	Disclosure SEC source: 0001209191-20-064573 · doc4.xml · nonDerivative · entry 2 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,813 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.10 to $35.57 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 16, 2020 Filed Dec 19, 2020 01:27 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionCommon Stock	1,000	$4.32	$4,320.00	Disclosure SEC source: 0001209191-20-064573 · doc4.xml · nonDerivative · entry 1 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 10, 2020 Filed Dec 12, 2020 00:13 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionStock Option (right to buy Common Stock) · Derivative	600	$0.00 Strike: $4.32	$0.00	Disclosure SEC source: 0001209191-20-063068 · doc4.xml · derivative · entry 4 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,185 Underlying: Common Stock · 600 shares Expires 2028-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning January 14, 2019, with 100% of the total shares vested and exercisable on December 14, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
December 10, 2020 Filed Dec 12, 2020 00:13 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	6,427	$35.41	$227,606.42	Disclosure SEC source: 0001209191-20-063068 · doc4.xml · nonDerivative · entry 3 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 632,047 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.22 to $35.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document
December 10, 2020 Filed Dec 12, 2020 00:13 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	600	$35.49	$21,292.02	Disclosure SEC source: 0001209191-20-063068 · doc4.xml · nonDerivative · entry 2 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,813 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.45 to $35.55 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 10, 2020 Filed Dec 12, 2020 00:13 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionCommon Stock	600	$4.32	$2,592.00	Disclosure SEC source: 0001209191-20-063068 · doc4.xml · nonDerivative · entry 1 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 01, 2020 Filed Dec 4, 2020 02:46 UTC	Morphic Holding, Inc. MORF · Entity 88114	Exercise / conversionStock Option (right to buy Common Stock) · Derivative	4,000	$0.00 Strike: $4.32	$0.00	Disclosure SEC source: 0001209191-20-061738 · doc4.xml · derivative · entry 4 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,785 Underlying: Common Stock · 4,000 shares Expires 2028-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning January 14, 2019, with 100% of the total shares vested and exercisable on December 14, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
December 01, 2020 Filed Dec 4, 2020 02:46 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	4,000	$31.24	$124,961.20	Disclosure SEC source: 0001209191-20-061738 · doc4.xml · nonDerivative · entry 3 Tipirneni Praveen P. · CIK 0001779978 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Praveen P. Tipirneni Irrevocable Trust of 2019 Disclosed balance after: 638,474 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.91 to $31.85 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Sonali N. Shah, Trustee of The Praveen P. Tipirneni Irrevocable Trust of 2019. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.